CAM
IMVT icon

Creekmur Asset Management’s Immunovant IMVT Stock Holding History

Creekmur Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-644
Closed -$20.8K – 1111
2024
Q1 		$20.8K Buy
644
+134
+26% +$4.89K 0.01% 375
2023
Q4 		$21.5K Buy
+510
New +$18.8K 0.01% 415

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Creekmur Asset Management's IMVT Position: Q2 2024 in Review

Creekmur Asset Management sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 644 shares — an estimated $20.8K sold.

Creekmur Asset Management first reported a position in IMVT in Q4 2023 and held it in 2 quarters. The position peaked at $21.5K in Q4 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Creekmur Asset Management reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Creekmur Asset Management sold 644 Immunovant shares in Q2 2024, an estimated $20.8K.
  • Creekmur Asset Management first reported a position in Immunovant in Q4 2023 and held it in 2 quarters.
  • Creekmur Asset Management's Immunovant position peaked at $21.5K in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Creekmur Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.